100
Participants
Start Date
July 31, 2006
Primary Completion Date
February 28, 2009
Study Completion Date
March 31, 2009
Erlotinib
erlotinib 150 mg/day once daily
Satraplatin
"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
Fox Chase Cancer Center, Philadelphia
Memorial Cancer Institute, Hollywood
University of Miami Sylvester Cancer Center, Miami
Cleveland Clinic Foundation, Cleveland
Gabrail Cancer Center, Canton
Signal Point Hematology/Oncology, Middleton
Rush University Medical Center, Chicago
Highlands Oncology Group, Bentonville
Kenmar Research Institute, Los Angeles
Scripps Clinic, La Jolla
Pacific Cancer Medical Center, Anaheim
McGill University, Montreal
Princess Margaret Hospital, Toronto
Hospital San Borja Arriaran, Santiago
Instituto Nacional del Cancer, Santiago
Research Center, Santiago
Lead Sponsor
Agennix
INDUSTRY